Learning Objectives

By the end of this chapter, learners will be able to:
1. Define rapidly progressive glomerulonephritis and recognize its clinical urgency
2. Understand the pathophysiology of crescentic glomerulonephritis
3. Classify RPGN into three major types based on immunofluorescence patterns
4. Recognize the clinical presentation and laboratory findings
5. Describe the urgent diagnostic approach and when to initiate treatment
6. Outline aggressive treatment protocols for different types of RPGN
7. Understand the prognosis and factors affecting outcomes
8. Recognize when dialysis and supportive care are needed

Introduction and Definition

Rapidly progressive glomerulonephritis (RPGN) represents one of the most urgent medical emergencies in nephrology, characterized by rapid deterioration of renal function over days to weeks, often accompanied by nephritic syndrome features. The hallmark pathological finding is crescentic glomerulonephritis, where more than 50% of glomeruli contain crescents – proliferative lesions within Bowman’s space composed of proliferating epithelial cells, infiltrating macrophages, and fibrin deposits.

The clinical definition of RPGN requires a rapid decline in glomerular filtration rate, typically defined as a doubling of serum creatinine within three months, though many cases progress much more rapidly over days to weeks. Without prompt recognition and aggressive treatment, RPGN frequently progresses to end-stage renal disease, making early diagnosis and intervention crucial for preserving renal function.

RPGN can occur at any age but shows distinct patterns across different age groups and geographic regions. The condition affects both sexes, though certain subtypes show gender predilections. The incidence varies globally, with some forms being more common in specific populations or geographic areas.

The urgency of RPGN cannot be overstated. Unlike many other forms of glomerulonephritis where treatment can be delayed for definitive diagnosis, RPGN often requires initiation of immunosuppressive therapy based on clinical suspicion alone, as delays in treatment are associated with irreversible renal damage and poor outcomes.

Pathophysiology

The pathophysiology of RPGN centers on severe acute glomerular injury that triggers an intense inflammatory response, leading to the formation of crescents within Bowman’s space. Crescents represent a common final pathway of severe glomerular injury, regardless of the initial inciting mechanism.

Crescent formation begins with severe damage to the glomerular capillary wall, leading to disruption of the glomerular basement membrane and allowing inflammatory cells, plasma proteins, and coagulation factors to enter Bowman’s space. This breach in the filtration barrier triggers a cascade of events including complement activation, coagulation cascade activation, and inflammatory cell recruitment.

The crescents themselves are composed of several cell types and components. Proliferating parietal epithelial cells form the primary cellular component, stimulated by various growth factors and cytokines released during the inflammatory process. Infiltrating macrophages contribute to the inflammatory response and tissue damage through release of proteases, reactive oxygen species, and pro-inflammatory mediators.

Fibrin deposition within crescents results from activation of the coagulation cascade and impaired fibrinolysis. The fibrin provides a scaffold for cellular proliferation and contributes to the organization and eventual fibrosis of the crescents. Platelets may also be trapped within the crescents, further contributing to the thrombotic and inflammatory processes.

The inflammatory response in RPGN involves multiple pathways and mediators. Complement activation plays a central role, with generation of chemotactic factors that recruit inflammatory cells and membrane attack complexes that directly damage glomerular cells. Cytokines such as interleukin-1, tumor necrosis factor-alpha, and interferon-gamma amplify the inflammatory response and promote cellular proliferation.

The rapid progression characteristic of RPGN results from the extensive nature of the glomerular injury and the self-perpetuating inflammatory process. As more glomeruli become involved and crescents organize into fibrous tissue, the remaining functional nephron mass decreases rapidly, leading to progressive renal failure.

Different mechanisms can trigger the initial glomerular injury in RPGN, leading to the classification into three major types based on immunofluorescence patterns. Type I RPGN involves anti-glomerular basement membrane (anti-GBM) antibodies, Type II involves immune complex deposition, and Type III is characterized by minimal or absent immune deposits (pauci-immune), usually associated with antineutrophil cytoplasmic antibodies (ANCA).

Classification and Types

RPGN is classified into three major types based on immunofluorescence microscopy patterns, each representing different pathophysiological mechanisms and requiring different treatment approaches.

Type I RPGN (Anti-GBM Disease) accounts for approximately 10-20% of RPGN cases and is caused by antibodies directed against the α3 chain of type IV collagen in the glomerular basement membrane. This condition, also known as Goodpasture’s disease when pulmonary involvement is present, typically affects young men and older women in a bimodal age distribution.

The anti-GBM antibodies bind to specific epitopes on the α3 chain of type IV collagen, which is present in both glomerular and alveolar basement membranes. This binding triggers complement activation and inflammatory cell recruitment, leading to rapidly progressive glomerulonephritis and often pulmonary hemorrhage. The linear pattern of IgG deposition along the glomerular basement membrane on immunofluorescence is characteristic of this condition.

Type I RPGN has the most aggressive course among the three types, with many patients presenting with advanced renal failure. The presence of circulating anti-GBM antibodies can be detected by enzyme-linked immunosorbent assay (ELISA) or radioimmunoassay, providing a rapid diagnostic test that can guide urgent treatment decisions.

Type II RPGN (Immune Complex-Mediated) accounts for approximately 40-50% of RPGN cases and results from deposition of immune complexes within the glomeruli. The immune complexes can be formed in circulation and subsequently deposited in the glomeruli, or they can form in situ within the glomerular capillaries.

Various conditions can cause Type II RPGN, including systemic lupus erythematosus (particularly Class IV lupus nephritis), post-infectious glomerulonephritis, membranoproliferative glomerulonephritis, IgA nephropathy, and cryoglobulinemic glomerulonephritis. The immunofluorescence pattern shows granular deposition of immunoglobulins and complement components.

The clinical presentation and prognosis of Type II RPGN depend largely on the underlying condition. Lupus nephritis may respond well to aggressive immunosuppressive therapy, while post-infectious causes may have a more favorable prognosis with supportive care alone.

Type III RPGN (Pauci-Immune) accounts for approximately 50-60% of RPGN cases and is characterized by minimal or absent immune deposits on immunofluorescence microscopy. The majority of cases are associated with ANCA, making this condition part of the spectrum of ANCA-associated vasculitis.

ANCA-associated RPGN includes three main conditions: granulomatosis with polyangiitis (formerly Wegener’s granulomatosis), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome). These conditions are systemic vasculitides that affect small vessels, including glomerular capillaries.

Two main ANCA patterns are recognized: c-ANCA (cytoplasmic pattern) associated with antibodies to proteinase 3 (PR3), and p-ANCA (perinuclear pattern) associated with antibodies to myeloperoxidase (MPO). The ANCA pattern and specificity can provide important diagnostic and prognostic information.

Type III RPGN typically affects older adults, with a mean age of 50-60 years, and shows a slight male predominance. The condition often involves multiple organ systems, and patients may present with constitutional symptoms, respiratory tract involvement, skin lesions, or peripheral neuropathy in addition to glomerulonephritis.

Clinical Manifestations

The clinical presentation of RPGN is characterized by the rapid onset of symptoms related to acute glomerulonephritis combined with signs of rapidly declining renal function. The presentation can be dramatic, with patients often seeking medical attention due to the acute nature and severity of their symptoms.

Oliguria or anuria is a common and concerning feature, with many patients noticing a significant decrease in urine output over days to weeks. The oliguria reflects the severe reduction in glomerular filtration rate and contributes to fluid retention and electrolyte abnormalities. In some cases, patients may maintain normal urine output despite significant loss of renal function.

Hematuria is typically present and may be gross or microscopic. The urine often appears dark, tea-colored, or cola-colored due to the presence of red blood cells that have been altered during passage through the nephron. Urinalysis typically shows red blood cell casts, which are pathognomonic of glomerular bleeding and help distinguish RPGN from other causes of acute kidney injury.

Proteinuria is present but is usually less severe than in nephrotic syndrome, typically ranging from 1-3 grams per day. However, some patients may present with nephrotic-range proteinuria, particularly in Type II RPGN associated with lupus nephritis or other immune complex diseases.

Edema develops rapidly due to sodium and water retention and may be severe. The edema typically begins in dependent areas and the face, particularly around the eyes, and can progress to involve the entire body. Pulmonary edema may develop due to volume overload and can be life-threatening.

Hypertension is common and often severe, reflecting the acute volume expansion and activation of the renin-angiotensin system. The blood pressure elevation can occur rapidly and may be associated with complications such as hypertensive encephalopathy, seizures, or heart failure. Some patients may present with hypertensive emergency requiring immediate intervention.

Constitutional symptoms are frequently present and may include fatigue, weakness, nausea, vomiting, and decreased appetite. These symptoms reflect both the uremic state and the underlying inflammatory process. Fever may be present, particularly in cases associated with systemic vasculitis or infections.

Respiratory symptoms may occur in patients with pulmonary involvement, particularly in anti-GBM disease (Goodpasture’s syndrome) and ANCA-associated vasculitis. Patients may experience dyspnea, cough, hemoptysis, or chest pain. Pulmonary hemorrhage can be life-threatening and requires immediate recognition and treatment.

Systemic manifestations depend on the underlying cause and may include skin rashes, arthralgia, peripheral neuropathy, or involvement of other organ systems. These features are particularly common in ANCA-associated vasculitis and systemic lupus erythematosus.

The rapidity of symptom onset is a key feature that distinguishes RPGN from other forms of chronic kidney disease. Patients or their families often report that symptoms developed over days to weeks rather than months to years, and this history should raise immediate suspicion for RPGN.

Diagnostic Approach

The diagnostic evaluation of suspected RPGN requires urgent and systematic assessment, as delays in diagnosis and treatment can result in irreversible renal damage. The approach must balance the need for rapid treatment initiation with the importance of obtaining adequate diagnostic information to guide therapy.

The history should focus on the timeline of symptom development, with particular attention to the rapidity of onset. Recent infections, medication use, and symptoms suggestive of systemic diseases should be explored. Family history of kidney disease or autoimmune conditions may provide important clues.

Physical examination should assess for signs of volume overload, hypertension, and systemic disease. Particular attention should be paid to the presence of rashes, joint swelling, lymphadenopathy, or signs of pulmonary involvement. Fundoscopic examination may reveal hypertensive retinopathy or other abnormalities.

Laboratory evaluation should begin immediately and include complete blood count, comprehensive metabolic panel, and urinalysis with microscopy. The presence of red blood cell casts in the urine is particularly important as it confirms glomerular origin of the hematuria and supports the diagnosis of glomerulonephritis.

Serum creatinine levels should be compared to previous values when available to assess the rate of decline in renal function. A doubling of creatinine within three months meets the definition of RPGN, though many cases progress much more rapidly. Blood urea nitrogen levels are typically elevated and may be disproportionately high relative to creatinine due to volume depletion.

Proteinuria should be quantified through either 24-hour urine collection or spot protein-to-creatinine ratio. While proteinuria is typically less severe than in nephrotic syndrome, some patients may have nephrotic-range proteinuria, particularly in immune complex-mediated disease.

Serological studies are crucial for determining the type of RPGN and should be obtained urgently. Anti-GBM antibodies should be measured in all patients with suspected RPGN, as this test can be performed rapidly and positive results indicate the need for immediate aggressive treatment including plasmapheresis.

ANCA testing should include both immunofluorescence pattern (c-ANCA vs p-ANCA) and specific antigen testing (PR3 and MPO antibodies). These tests help diagnose ANCA-associated vasculitis and can guide treatment decisions. The results may take longer to obtain than anti-GBM antibodies, but treatment should not be delayed while awaiting results.

Complement levels (C3, C4, CH50) help identify immune complex-mediated disease. Low complement levels suggest conditions such as lupus nephritis, post-infectious glomerulonephritis, or membranoproliferative glomerulonephritis. Normal complement levels are typical of ANCA-associated vasculitis and anti-GBM disease.

Additional serological studies may include antinuclear antibodies (ANA), anti-double-stranded DNA antibodies, antistreptolysin O (ASO) titers, and hepatitis serologies, depending on the clinical presentation and suspected underlying cause.

Imaging studies should include chest X-ray to assess for pulmonary edema, infiltrates, or hemorrhage. Renal ultrasound can assess kidney size and structure and rule out obstruction, though findings are often normal in acute RPGN.

Renal biopsy is often necessary for definitive diagnosis and should be performed urgently when possible. However, treatment should not be delayed while awaiting biopsy results in patients with clinical features strongly suggestive of RPGN, particularly if anti-GBM antibodies are positive or if there is evidence of pulmonary-renal syndrome.

The biopsy should be processed for light microscopy, immunofluorescence, and electron microscopy. The percentage of glomeruli with crescents should be determined, as this has prognostic significance. The presence of fibrinoid necrosis, endocapillary proliferation, and the pattern of immune deposits help determine the underlying cause.

Treatment Strategies

The treatment of RPGN requires immediate and aggressive intervention, as delays in therapy are associated with irreversible renal damage and poor outcomes. The approach involves both immunosuppressive therapy to halt the inflammatory process and supportive care to manage complications and preserve remaining renal function.

The decision to initiate treatment should be based on clinical suspicion and should not be delayed while awaiting biopsy results or complete serological studies. In patients with strong clinical evidence of RPGN, particularly those with positive anti-GBM antibodies or pulmonary-renal syndrome, treatment should begin immediately.

Corticosteroids form the cornerstone of treatment for all types of RPGN and should be initiated as soon as the diagnosis is suspected. The standard regimen typically involves high-dose intravenous methylprednisolone (500-1000 mg daily for 3-5 days) followed by high-dose oral prednisone (1 mg/kg/day, maximum 60-80 mg daily). The high initial doses are necessary to rapidly suppress the intense inflammatory response.

Cyclophosphamide is the most commonly used cytotoxic agent for RPGN and is typically combined with corticosteroids for induction therapy. The standard regimen involves oral cyclophosphamide (2 mg/kg/day, adjusted for age and renal function) or intravenous pulse therapy (15 mg/kg every 2-4 weeks). Intravenous administration may be preferred in older patients or those at higher risk for toxicity.

Plasmapheresis (plasma exchange) is indicated in specific situations and involves the removal of circulating pathogenic antibodies and inflammatory mediators. It is most clearly beneficial in anti-GBM disease, where it removes circulating anti-GBM antibodies and should be performed daily for 10-14 days or until antibodies become undetectable.

In ANCA-associated vasculitis, plasmapheresis is typically reserved for patients with severe renal involvement (creatinine >500 μmol/L or 5.7 mg/dL) or pulmonary hemorrhage. The evidence for benefit in these situations is less clear than in anti-GBM disease, but it is often used as adjunctive therapy in severe cases.

The treatment approach varies somewhat based on the type of RPGN. Type I RPGN (anti-GBM disease) requires the most aggressive treatment with the combination of corticosteroids, cyclophosphamide, and plasmapheresis. Treatment should be initiated immediately upon diagnosis, as delays are associated with poor renal outcomes.

Type II RPGN (immune complex-mediated) treatment depends on the underlying cause. Lupus nephritis typically requires aggressive immunosuppressive therapy similar to Type I RPGN, while post-infectious causes may require only supportive care. The specific treatment regimen should be tailored to the underlying condition.

Type III RPGN (ANCA-associated) treatment typically involves corticosteroids and cyclophosphamide for induction therapy. Rituximab has emerged as an alternative to cyclophosphamide for induction therapy and may be particularly useful in patients with contraindications to cyclophosphamide or relapsing disease.

Supportive care is crucial for all patients with RPGN and includes management of volume overload, hypertension, and electrolyte abnormalities. Diuretics may be necessary for volume management, though care must be taken to avoid volume depletion that could worsen renal function.

Antihypertensive therapy should target blood pressure control while preserving renal perfusion. ACE inhibitors or angiotensin receptor blockers may be beneficial for blood pressure control and potential renoprotection, though they should be used cautiously in patients with severe renal impairment.

Dialysis may be necessary for patients who present with severe renal failure, volume overload, or electrolyte abnormalities that cannot be managed medically. The need for dialysis at presentation does not preclude recovery of renal function with appropriate treatment, particularly if treatment is initiated promptly.

Monitoring and Response Assessment

Monitoring patients with RPGN requires frequent assessment of renal function, treatment response, and drug toxicity. The acute nature of the condition and the aggressive treatment regimens necessitate close observation and frequent laboratory monitoring.

Renal function should be monitored daily initially, with assessment of serum creatinine, blood urea nitrogen, and electrolytes. The goal is to halt the progression of renal failure and ideally achieve improvement in renal function. Stabilization of creatinine levels within the first few weeks of treatment is often the first sign of response.

Urinalysis should be performed regularly to monitor for improvement in hematuria and proteinuria. The disappearance of red blood cell casts and reduction in proteinuria are positive prognostic signs. However, these changes may lag behind improvement in renal function.

Serological markers should be monitored to assess treatment response. Anti-GBM antibodies should become undetectable with successful treatment, typically within 2-4 weeks of initiating plasmapheresis. ANCA titers may take longer to normalize and may not completely disappear, but significant reductions are associated with better outcomes.

Complete blood count should be monitored closely due to the myelosuppressive effects of cyclophosphamide. Leukopenia is common and may require dose reduction or temporary discontinuation of therapy. Thrombocytopenia may also occur and requires monitoring.

Liver function tests should be monitored as both cyclophosphamide and high-dose corticosteroids can affect liver function. Glucose levels require close monitoring due to the diabetogenic effects of corticosteroids, particularly in patients with pre-existing diabetes or risk factors.

Infection surveillance is crucial as the combination of immunosuppressive therapy and uremia increases infection risk. Patients should be monitored for signs of bacterial, viral, or opportunistic infections. Prophylactic measures such as pneumocystis prophylaxis may be indicated in patients receiving intensive immunosuppressive therapy.

Response to treatment is typically assessed at 2-4 weeks, though some improvement may be seen earlier. Complete response is defined as stabilization or improvement in renal function with resolution of active urinary sediment. Partial response involves improvement in renal function but with persistent abnormalities.

Lack of response to initial therapy may require modification of the treatment regimen, including higher doses of immunosuppressive agents, addition of plasmapheresis if not already being used, or consideration of alternative agents such as rituximab.

Prognosis and Outcomes

The prognosis of RPGN varies significantly based on several factors including the underlying type, severity at presentation, and promptness of treatment initiation. Understanding these prognostic factors is essential for patient counseling and treatment planning.

Overall, RPGN has a guarded prognosis, with many patients requiring long-term dialysis despite treatment. However, significant recovery of renal function is possible, particularly when treatment is initiated early in the disease course. The extent of recovery depends on the amount of irreversible damage that has occurred before treatment begins.

Type I RPGN (anti-GBM disease) generally has the poorest renal prognosis among the three types. Most patients require dialysis at presentation, and renal recovery is uncommon once dialysis is needed. However, early aggressive treatment can preserve some renal function in patients who present before requiring dialysis. The pulmonary component typically responds well to treatment.

Type II RPGN (immune complex-mediated) prognosis depends largely on the underlying cause. Lupus nephritis may have a relatively good prognosis with appropriate treatment, while other causes may have more variable outcomes. The presence of crescents in more than 50% of glomeruli is associated with worse prognosis regardless of the underlying cause.

Type III RPGN (ANCA-associated) has an intermediate prognosis, with remission achievable in 70-90% of patients with appropriate treatment. However, relapses are common, occurring in 30-50% of patients, and require ongoing monitoring and often retreatment. Long-term outcomes depend on the cumulative damage from initial presentation and subsequent relapses.

Several factors are associated with poor prognosis in RPGN. Advanced age is consistently associated with worse outcomes, likely due to reduced regenerative capacity and increased comorbidities. Severe renal impairment at presentation, particularly the need for dialysis, is associated with reduced likelihood of renal recovery.

The percentage of crescents on renal biopsy has important prognostic significance. Patients with crescents in more than 80% of glomeruli have a poor prognosis for renal recovery, while those with fewer crescents have better outcomes. The presence of chronic changes such as interstitial fibrosis and tubular atrophy also indicates worse prognosis.

Oliguria at presentation is associated with worse outcomes, likely reflecting more severe renal impairment. Patients who maintain urine output have better prognosis for renal recovery than those who develop oliguria or anuria.

The time from symptom onset to treatment initiation is crucial for outcomes. Delays in treatment are consistently associated with worse renal prognosis, emphasizing the importance of early recognition and prompt treatment initiation.

Pulmonary involvement, particularly pulmonary hemorrhage, is associated with increased mortality but does not necessarily worsen renal prognosis if the patient survives the acute episode. The pulmonary component typically responds well to treatment.

Long-term outcomes for patients who achieve remission include the risk of relapse, particularly in ANCA-associated vasculitis, and the development of chronic kidney disease even in patients who initially recover renal function. Cardiovascular disease is an important cause of long-term morbidity and mortality.

Special Considerations and Complications

RPGN presents several unique challenges and potential complications that require special attention and management. The aggressive nature of both the disease and its treatment creates a complex clinical scenario requiring expertise in multiple areas.

Pulmonary-renal syndrome represents one of the most serious presentations of RPGN, characterized by the combination of glomerulonephritis and pulmonary hemorrhage. This syndrome is most commonly seen in anti-GBM disease (Goodpasture’s syndrome) but can also occur in ANCA-associated vasculitis and rarely in other conditions.

Pulmonary hemorrhage can be life-threatening and requires immediate recognition and treatment. Patients may present with hemoptysis, dyspnea, and bilateral pulmonary infiltrates on chest imaging. The hemorrhage can progress rapidly and may require mechanical ventilation and intensive care management.

Treatment of pulmonary-renal syndrome requires immediate aggressive immunosuppressive therapy and plasmapheresis. High-dose corticosteroids should be initiated immediately, followed by cyclophosphamide and daily plasmapheresis. The pulmonary component typically responds more rapidly than the renal component.

Infection complications are common in RPGN patients due to the combination of uremia, immunosuppressive therapy, and often the need for invasive procedures such as dialysis access placement. Patients are at increased risk for bacterial, viral, and opportunistic infections.

Pneumocystis jirovecii pneumonia is a particular concern in patients receiving intensive immunosuppressive therapy, and prophylaxis with trimethoprim-sulfamethoxazole should be considered. Other opportunistic infections may also occur, and patients should be monitored closely for signs of infection.

Cardiovascular complications can occur due to volume overload, hypertension, and electrolyte abnormalities. Acute heart failure may develop rapidly and require aggressive management with diuretics, blood pressure control, and possibly dialysis for volume removal.

Neurological complications may include hypertensive encephalopathy, seizures, or stroke. These complications are more common in patients with severe hypertension and require immediate blood pressure control and supportive care.

Drug toxicity is a significant concern given the aggressive immunosuppressive regimens used in RPGN. Cyclophosphamide can cause bone marrow suppression, hemorrhagic cystitis, infertility, and increased risk of malignancy. Patients require close monitoring and supportive care to minimize these risks.

Corticosteroid toxicity includes hyperglycemia, increased infection risk, bone loss, and psychiatric effects. These complications are particularly concerning given the high doses and prolonged duration of therapy often required.

Plasmapheresis complications can include bleeding due to anticoagulation, electrolyte abnormalities, and rarely, allergic reactions to replacement fluids. Vascular access complications may also occur, particularly in patients requiring prolonged treatment.

Pregnancy considerations are important for women of childbearing age with RPGN. Cyclophosphamide is teratogenic and can cause infertility, making fertility preservation discussions important before treatment initiation. Alternative agents such as rituximab may be considered in pregnant patients, though experience is limited.

Summary

Rapidly progressive glomerulonephritis represents a true medical emergency in nephrology, characterized by rapid deterioration of renal function over days to weeks with crescentic glomerulonephritis on biopsy. The condition is classified into three types based on immunofluorescence patterns: Type I (anti-GBM), Type II (immune complex-mediated), and Type III (pauci-immune/ANCA-associated).

The pathophysiology involves severe acute glomerular injury leading to disruption of the glomerular basement membrane and formation of crescents within Bowman’s space. The crescents are composed of proliferating epithelial cells, infiltrating macrophages, and fibrin deposits, and their presence in more than 50% of glomeruli defines crescentic glomerulonephritis.

Clinical presentation typically includes oliguria, hematuria with red blood cell casts, proteinuria, edema, and hypertension, with rapid onset over days to weeks. Pulmonary involvement may occur, particularly in anti-GBM disease and ANCA-associated vasculitis, creating a pulmonary-renal syndrome that can be life-threatening.

Diagnosis requires urgent evaluation including urinalysis, renal function assessment, and serological studies including anti-GBM antibodies and ANCA. Renal biopsy is often necessary for definitive diagnosis but should not delay treatment initiation in patients with strong clinical suspicion.

Treatment involves aggressive immunosuppressive therapy with corticosteroids and cyclophosphamide, with plasmapheresis added for anti-GBM disease and severe ANCA-associated vasculitis. Treatment should be initiated immediately upon diagnosis, as delays are associated with irreversible renal damage.

Prognosis varies by type, with anti-GBM disease having the poorest renal outcomes and ANCA-associated disease having intermediate prognosis with good remission rates but high relapse risk. Early treatment initiation is the most important factor for preserving renal function.

Complications include pulmonary hemorrhage, infections, cardiovascular events, and drug toxicity. Close monitoring and supportive care are essential components of management. Despite aggressive treatment, many patients require long-term dialysis, emphasizing the importance of early recognition and prompt intervention.

Clinical Pearls

1. Time is Kidney Function: RPGN is a nephrology emergency – every hour of delay in treatment increases the risk of irreversible renal damage. Start treatment on clinical suspicion, don’t wait for biopsy.

2. Crescent Percentage Matters: >50% crescents defines RPGN; >80% crescents indicates very poor prognosis for renal recovery regardless of treatment.

3. Anti-GBM Antibody Urgency: Positive anti-GBM antibodies require immediate triple therapy (steroids + cyclophosphamide + plasmapheresis) – this is the most aggressive form of RPGN.

4. Dialysis Doesn’t Mean Hopeless: Need for dialysis at presentation doesn’t preclude renal recovery if treatment is started promptly, especially in ANCA-associated disease.

5. Pulmonary-Renal Syndrome Recognition: Hemoptysis + acute glomerulonephritis = medical emergency requiring immediate aggressive treatment and ICU monitoring.

6. ANCA Pattern Significance: c-ANCA/PR3 typically associated with upper respiratory tract involvement; p-ANCA/MPO more commonly limited to kidneys and lungs.

7. Complement Pattern Clues: Normal complements suggest ANCA vasculitis or anti-GBM disease; low C3/C4 suggests lupus or immune complex disease.

8. Oliguria as Poor Prognostic Sign: Patients who maintain urine output have better prognosis than those who develop oliguria/anuria.

9. Age Impact on Outcomes: Elderly patients have worse prognosis due to reduced regenerative capacity and increased comorbidities.

10. Infection Vigilance: Intensive immunosuppression + uremia = high infection risk. Consider PCP prophylaxis and monitor closely for opportunistic infections.

11. Cyclophosphamide Toxicity: Monitor for hemorrhagic cystitis (ensure adequate hydration), bone marrow suppression, and discuss fertility preservation before treatment.

12. Relapse Risk in ANCA Disease: 30-50% of ANCA patients relapse; lifelong monitoring required even after achieving remission.

Recommended Diagrams and Images:

1. RPGN Classification Flowchart: Decision tree showing Type I (anti-GBM), Type II (immune complex), and Type III (pauci-immune) classification
2. Crescent Formation Pathophysiology: Step-by-step diagram showing GBM disruption leading to crescent formation
3. Immunofluorescence Patterns: Comparison of linear (anti-GBM), granular (immune complex), and negative (pauci-immune) patterns
4. Treatment Algorithm: Emergency management flowchart for suspected RPGN
5. Pulmonary-Renal Syndrome Recognition: Clinical presentation and immediate management steps
6. Prognostic Factors Chart: Visual representation of factors affecting outcomes
7. ANCA Testing Interpretation: c-ANCA vs p-ANCA patterns and associated diseases
8. Plasmapheresis Indications: Clear guidelines for when to initiate plasma exchange
9. Monitoring Timeline: Schedule for laboratory monitoring during treatment
10. Complication Management: Flowchart for managing common complications

Histopathology Images:

• Light microscopy showing crescentic glomerulonephritis
• Immunofluorescence patterns (linear, granular, negative)
• Electron microscopy showing GBM disruption
• Different stages of crescent formation (cellular to fibrous)

Clinical Photography:

• Chest X-rays showing pulmonary hemorrhage
• Urine samples showing gross hematuria
• Clinical signs of volume overload

Laboratory Images:

• Urinalysis showing RBC casts
• ANCA immunofluorescence patterns
• Anti-GBM antibody test results

Slide 1: Title Slide

• Title: Rapidly Progressive Glomerulonephritis (RPGN)
• Subtitle: A Nephrology Emergency – Recognition and Urgent Management
• NephroHub Watermark

Slide 2: Learning Objectives

• Define RPGN and recognize clinical urgency
• Classify RPGN into three major types
• Understand pathophysiology of crescentic GN
• Describe urgent diagnostic approach
• Outline aggressive treatment protocols

Slide 3: Definition and Clinical Urgency

• Rapid decline in GFR over days to weeks

• 50% crescents on renal biopsy

• Doubling of creatinine within 3 months
• EMERGENCY: Time is kidney function

Slide 4: Why RPGN is an Emergency

• Irreversible renal damage within days
• High risk of ESRD without treatment
• Treatment delay = worse outcomes
• Start treatment on clinical suspicion

Slide 5: Pathophysiology Overview

• Severe glomerular capillary injury
• GBM disruption and Bowman’s space breach
• Inflammatory cell infiltration
• Crescent formation and organization

Slide 6: Crescent Formation Process

• GBM disruption allows protein/cell entry
• Parietal epithelial cell proliferation
• Macrophage infiltration
• Fibrin deposition and organization

Slide 7: RPGN Classification System

• Type I: Anti-GBM (linear IF)
• Type II: Immune complex (granular IF)
• Type III: Pauci-immune (negative IF)
• Based on immunofluorescence patterns

Slide 8: Type I RPGN (Anti-GBM Disease)

• 10-20% of RPGN cases
• Goodpasture’s syndrome when pulmonary involvement
• Linear IgG on immunofluorescence
• Worst prognosis, requires immediate treatment

Slide 9: Type II RPGN (Immune Complex)

• 40-50% of RPGN cases
• Lupus nephritis, post-infectious GN, MPGN
• Granular immunofluorescence pattern
• Treatment depends on underlying cause

Slide 10: Type III RPGN (Pauci-immune)

• 50-60% of RPGN cases
• ANCA-associated vasculitis
• Minimal immune deposits
• c-ANCA/PR3 vs p-ANCA/MPO patterns

Slide 11: Clinical Presentation

• Rapid onset oliguria/anuria
• Gross hematuria with RBC casts
• Severe hypertension and edema
• Constitutional symptoms
• Possible pulmonary involvement

Slide 12: Pulmonary-Renal Syndrome

• Glomerulonephritis + pulmonary hemorrhage
• Most common in anti-GBM disease
• Can occur in ANCA vasculitis
• Life-threatening emergency

Slide 13: Urgent Diagnostic Approach

• Don’t delay treatment for diagnosis
• Immediate: CBC, BMP, urinalysis
• Urgent: Anti-GBM, ANCA, complements
• Chest X-ray for pulmonary involvement
• Renal biopsy when possible

Slide 14: Laboratory Findings

• Rising creatinine (rapid progression)
• RBC casts in urine (pathognomonic)
• Proteinuria (usually <3.5 g/day)
• Specific antibodies (anti-GBM, ANCA)

Slide 15: Emergency Treatment Protocol

• Start immediately on clinical suspicion
• High-dose IV methylprednisolone
• Cyclophosphamide (oral or IV)
• Plasmapheresis for specific indications

Slide 16: Corticosteroid Therapy

• Methylprednisolone 500-1000 mg IV x 3-5 days
• Followed by prednisone 1 mg/kg/day
• Rapid anti-inflammatory effect
• Start before other agents

Slide 17: Cyclophosphamide Regimens

• Oral: 2 mg/kg/day (adjust for age/renal function)
• IV pulse: 15 mg/kg every 2-4 weeks
• Monitor for bone marrow suppression
• Fertility counseling before treatment

Slide 18: Plasmapheresis Indications

• Mandatory: Anti-GBM disease
• Consider: Severe ANCA vasculitis
• Consider: Pulmonary hemorrhage
• Daily for 10-14 days or until antibodies clear

Slide 19: Type-Specific Treatment

• Type I: Steroids + cyclophosphamide + plasmapheresis
• Type II: Depends on underlying cause
• Type III: Steroids + cyclophosphamide ± plasmapheresis

Slide 20: Monitoring and Response

• Daily creatinine initially
• CBC for cyclophosphamide toxicity
• Antibody levels (anti-GBM, ANCA)
• Urinalysis for improvement
• Infection surveillance

Slide 21: Prognostic Factors

• Good: Early treatment, younger age, preserved urine output
• Poor: Dialysis requirement, >80% crescents, oliguria
• Critical: Time to treatment initiation

Slide 22: Complications Management

• Pulmonary hemorrhage: ICU care
• Infections: High vigilance, prophylaxis
• Drug toxicity: Close monitoring
• Cardiovascular: Volume/BP management

Slide 23: Long-term Outcomes

• Type I: Poor renal prognosis
• Type II: Variable by underlying cause
• Type III: Good remission rates, high relapse risk
• Many require long-term dialysis

Slide 24: Key Emergency Messages

• RPGN = Nephrology Emergency
• Start treatment immediately
• Don’t wait for biopsy results
• Time is kidney function
• Early recognition saves kidneys

Slide 25: Case Study

• Emergency presentation
• Rapid diagnostic workup
• Immediate treatment initiation
• Outcome and lessons learned

Slide 26: Summary and Action Points

• Recognize RPGN urgency
• Immediate treatment protocols
• Type-specific management
• Monitoring and complication management

Question 1

A 65-year-old man presents with a 1-week history of oliguria, gross hematuria, and dyspnea. Creatinine has risen from 1.2 to 4.8 mg/dL. Anti-GBM antibodies are positive. What is the most appropriate immediate treatment?

A) ACE inhibitors and supportive care
B) Corticosteroids alone
C) Corticosteroids and cyclophosphamide
D) Corticosteroids, cyclophosphamide, and plasmapheresis
E) Dialysis only

Correct Answer: D) Corticosteroids, cyclophosphamide, and plasmapheresis

Explanation: Anti-GBM disease requires immediate triple therapy with corticosteroids, cyclophosphamide, and plasmapheresis to remove circulating antibodies. This is the most aggressive form of RPGN requiring urgent treatment.

Question 2

What percentage of glomeruli must contain crescents to define crescentic glomerulonephritis?

A) >25%
B) >50%
C) >75%
D) >90%
E) 100%

Correct Answer: B) >50%

Explanation: Crescentic glomerulonephritis is defined by the presence of crescents in more than 50% of glomeruli on renal biopsy. This threshold distinguishes RPGN from other forms of glomerulonephritis.

Question 3

Which immunofluorescence pattern is characteristic of anti-GBM disease?

A) Granular IgG and C3 deposition
B) Linear IgG deposition along GBM
C) Mesangial IgA deposition
D) No immune deposits (pauci-immune)
E) Subepithelial spike formation

Correct Answer: B) Linear IgG deposition along GBM

Explanation: Anti-GBM disease shows a characteristic linear pattern of IgG deposition along the glomerular basement membrane on immunofluorescence, distinguishing it from other types of RPGN.

Question 4

A patient with RPGN has normal C3 and C4 levels with positive c-ANCA/PR3. What is the most likely diagnosis?

A) Post-infectious glomerulonephritis
B) Lupus nephritis
C) Anti-GBM disease
D) Granulomatosis with polyangiitis
E) Membranoproliferative glomerulonephritis

Correct Answer: D) Granulomatosis with polyangiitis

Explanation: Normal complement levels with positive c-ANCA/PR3 is characteristic of granulomatosis with polyangiitis (formerly Wegener’s), a form of ANCA-associated vasculitis causing Type III RPGN.

Question 5

When should treatment be initiated in suspected RPGN?

A) After renal biopsy confirmation
B) After serological results return
C) Only if creatinine >5 mg/dL
D) Immediately upon clinical suspicion
E) After ruling out other causes

Correct Answer: D) Immediately upon clinical suspicion

Explanation: RPGN is a medical emergency where delays in treatment lead to irreversible renal damage. Treatment should begin immediately upon clinical suspicion, not waiting for biopsy or complete serological results.

Question 6

Which factor is most strongly associated with poor prognosis in RPGN?

A) Age >65 years
B) Presence of hypertension
C) >80% crescents on biopsy
D) Proteinuria >3 g/day
E) Male gender

Correct Answer: C) >80% crescents on biopsy

Explanation: The percentage of crescents on renal biopsy is the strongest predictor of renal outcome. Patients with >80% crescents have very poor prognosis for renal recovery regardless of treatment.

Question 7

What is the most common type of RPGN?

A) Type I (anti-GBM)
B) Type II (immune complex)
C) Type III (pauci-immune)
D) Mixed type
E) Idiopathic

Correct Answer: C) Type III (pauci-immune)

Explanation: Type III (pauci-immune) RPGN, usually ANCA-associated, accounts for 50-60% of RPGN cases, making it the most common type, particularly in older adults.

Question 8

A patient with RPGN develops hemoptysis and bilateral pulmonary infiltrates. What is the most likely diagnosis?

A) Pneumonia
B) Pulmonary edema
C) Pulmonary embolism
D) Pulmonary-renal syndrome
E) Drug-induced pneumonitis

Correct Answer: D) Pulmonary-renal syndrome

Explanation: The combination of RPGN with hemoptysis and pulmonary infiltrates suggests pulmonary-renal syndrome, most commonly seen in anti-GBM disease or ANCA-associated vasculitis.

Question 9

Which medication requires the most careful monitoring for bone marrow suppression in RPGN treatment?

A) Prednisone
B) Cyclophosphamide
C) Mycophenolate mofetil
D) Rituximab
E) Plasmapheresis

Correct Answer: B) Cyclophosphamide

Explanation: Cyclophosphamide is the most myelosuppressive agent used in RPGN treatment and requires frequent CBC monitoring for leukopenia and thrombocytopenia.

Question 10

What is the typical duration of daily plasmapheresis in anti-GBM disease?

A) 3-5 days
B) 7-10 days
C) 10-14 days or until antibodies undetectable
D) 21-28 days
E) Until renal function improves

Correct Answer: C) 10-14 days or until antibodies undetectable

Explanation: Plasmapheresis in anti-GBM disease is typically performed daily for 10-14 days or until anti-GBM antibodies become undetectable, whichever comes first.

Visual Learning Workflow